Our findings hinted that the genetic mutations occurred in ALKBH1/2/3/4/5/6/7/8 and FTO in HCC patients, with altered rates of 15, 5, 5, 11, 17, 8, 6, 8, and 12%, respectively (Fig. 5A). The gene discussed is FTO; the disease is hepatocellular carcinoma.